Publications found:
113,017
Sort by:
ROCHE, GLAXOSMITHKLINE - Exciting Data on TDM1 - Will Keep Competition at Bay
US$ 140.00
... months compared to Herceptin + docetaxel (14.2 m vs. 9.2 m- Table 1). The safety data as well, is very convincing as T-DM1 cut Grade 3 or more adverse effects ... 50% (46.4% vs. 89.4%). With T-DM1 and pertuzumab arrows in its quiver, Roche is well poised to sustain its breast cancer franchise beyond Herceptin ...
September 2011
4 pages
Observing Patients Online: the changing face of research
US$ 595.00
For years, patients have shouted to be heard. But as online patient communities, chat rooms and forums have gained popularity—and political clout—their voices are resonating.
Now being used t...
September 2011
47 pages
The 2011 Global Orthopedics Market Dynamics and Trends
US$ 1,480.00
... categories. In addition, the report presents a concise review of the major U.S. and international trends with potentially significant impact on the orthopedics market during the next five years, including industry consolidation, market globalization, environmental regulations, etc. The analysis of major ...
September 2011
53 pages
Ear Care in Turkey
US$ 990.00
... OTC products to be sold in supermarkets and drugstore chains. Euromonitor International's Ear Care in Turkey report offers a comprehensive guide to the size and shape of the ... data. Why buy this report? Get a detailed picture of the Ear Care market; Pinpoint growth sectors and identify factors driving change ...
September 2011
22 pages
Medicated Skin Care in Tunisia
US$ 990.00
... as anti-bacterial, lightening and sun protection products. Euromonitor International's Medicated Skin Care in Tunisia report offers a comprehensive guide to the size and shape of the ... and Allergy Remedies, Child-Specific Digestive Remedies, Child-Specific Medicated Skin Care, Cold Sore Treatments, Combination Products - Cough, Cold and Allergy ...
September 2011
19 pages
Medicated Skin Care in South Korea
US$ 990.00
... to female consumers in particular. As this issue becomes more... Euromonitor International's Medicated Skin Care in South Korea report offers a comprehensive guide to the size and shape of the ... and Allergy Remedies, Child-Specific Digestive Remedies, Child-Specific Medicated Skin Care, Cold Sore Treatments, Combination Products - Cough, Cold and Allergy ...
September 2011
29 pages
The European Orthopedics Market: Strategic Assessments of Leading Suppliers
US$ 7,600.00
The report provides strategic overview of the European orthopedics market, including forecasts for major market segments and product categories. In addition, ... of the major trends with potentially significant impact on the European orthopedics market during the next five years, including industry consolidation ...
September 2011
620 pages
The US Orthopedics Market: Strategic Assessments of Leading Suppliers
US$ 7,600.00
The report provides a strategic overview of the US orthopedics market, including forecasts for major market segments and product categories. In addition, the report presents a concise review of the major trends with potentially significant impact on the US ...
September 2011
620 pages
Vertex - Near Term Positive Long Term Neutral
US$ 140.00
... therapy area is heating up, Vertex (VRTX) will continue to have the edge for at least 3yrs. We expect most of the near term milestones related for ... read our report released on 23th September, 2011 on VRTX titled “Near Term Positive Long Term Neutral”.
September 2011
5 pages
Competitor Analysis: Novel Mitotic Kinase Inhibitors
US$ 550.00
... cell cycle, whereas CDK7 has dual roles as a CDK-activating kinase (CAK) and a regulator of the transcriptional machinery. CDK8 and CDK9 ... Inhibitors Corporate Novel Mitotic Kinase Inhibitor R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, ...
September 2011
62 pages
Competitor Analysis: Her2 and Her3 Receptor Antagonists
US$ 413.00
... active projects in research and development of molecules targeting the Her2 (ErbB2) and Her3 receptor. In addition, the report lists company-specific ... Antagonists Pan-Her Receptor Antagonists Corporate Her2 and Her3 Receptor Antagonist R&D Pipelines About La Merie About Competitor Analysis Series: The ...
September 2011
63 pages
Competitor Analysis: EGF-R Agonists and Antagonists
US$ 533.00
... -R and Her2 Receptor Antagonists Pan-ErbB (pan-Her) Receptor Antagonists Multi-Target EGF-R Antagonists Others Corporate EGF-R Agonist and Antagonist R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about ...
September 2011
73 pages
Therapeutic Apheresis: Market Research Report
US$ 4,500.00
This report analyzes the US market for Therapeutic Apheresis in US$ Thousand by the following procedures: Photopheresis, Plasmapheresis, Erythrocytapheresis, Plateletpheresis, Leukapheresis, and Lipidpheresis. The specific end-use segments analyzed are Neurology Disorders, Hematology & Oncology Disorders, ...
September 2011
126 pages
Apoptosis: Market Research Report
US$ 4,200.00
This report analyzes the worldwide markets for Apoptosis in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia ... Pte Ltd., S*BIO Pte Ltd, TopoTarget A/S, Xigen SA, and ?terna Zentaris GmbH. Market data and analytics are derived from primary and secondary research ...
September 2011
617 pages
Enteral Feeding Pumps: Market Research Report
US$ 4,200.00
This report analyzes the worldwide markets for Enteral Feeding Pumps in US$ Million. The report provides separate comprehensive analytics for the US ... AG, Moog Inc., Nestle HealthCare Nutrition, and Nutricia Advanced Medical Nutrition. Market data and analytics are derived from primary and secondary research. ...
September 2011
190 pages
Healthcare Antimicrobial Plastics: Market Research Report
US$ 4,200.00
This report analyzes the worldwide markets for Healthcare Antimicrobial Plastics in Metric Tons. The report provides separate comprehensive analytics for the US, ... International Ltd., PolyChem Alloy, Inc., Sciessent LLC, and Troy Corporation. Market data and analytics are derived from primary and secondary ...
September 2011
348 pages
PHARMASSET - Another Step Towards Success!
US$ 90.00
Pharmasset (VRUS) announced top line data of PSI-7977 PhIIb, PROTON ... read our report released on 13th September, 2011 on VRUS titled “Another Step Towards Success”.
September 2011
4 pages
New Research into Prescribing Practices
US$ 695.00
Every day, doctors make hundreds of decisions. Decisions that affect patient care, diagnosis, follow up and pharmaceuticals prescribed.
What influences those choices? When it comes to prescri...
August 2011
43 pages
Creating Compelling Market Access Stories
US$ 495.00
Who's in charge? It's an increasingly complex question faced by pharma companies when it comes to creating compelling value stories for payers. With governments tightening purse strings, generics flo...
August 2011
43 pages
Nu Skin Enterprises Inc in Consumer Health (World)
US$ 572.00
... the ageing process from the inside. The largest proportion of Nu Skin’s sales take place in Japan, but here it is facing declining sales ... company therefore is focusing on emerging markets such as China. Euromonitor International’s Nu Skin Enterprises Inc in Consumer Health (World) Company Profile offers detailed strategic analysis ...
August 2011
37 pages
Asia Pacific Markets for Dental Prosthetics and CAD/CAM 2011
US$ 8,495.00
In 2010, the total Asia-Pacific markets for dental prosthetics (made up of Japan, South Korea and Australia) were valued at $6.4 billion, a 0.1% increase over the previous year. The overall market CAD/CAM Prosthetics is estimated to grow at a double-digit rate over the forecast period. ...
August 2011
315 pages
Latest Product Innovations in Pet Care
US$ 2,000.00
... needs of consumers in mature and developing markets alike. Euromonitor International’s Latest Product Innovations in Pet Care global briefing offers an insight into the ... data. Why buy this report? Get a detailed picture of the Pet Care market; Pinpoint growth sectors and identify factors driving change; ...
August 2011
59 pages
Asthma and COPD Therapies: World Market 2011-2021
US$ 2,325.00
... charts and a research interview (shown in the accompanying lists). Asthma and COPD Therapies: World Market 2011-2021 shows you opportunities, challenges ... , France, UK, Spain, Italy, China and India Review R&D for asthma and COPD, assessing potential Investigate competition and opportunities influencing the ...
August 2011
138 pages
Extremities Market Report: 2011 Edition
US$ 700.00
... for a major share. The present report analyzes the global extremity market. The US extremity market is also presented in the report. The report analyzes the major growth drivers ...
August 2011
40 pages
Global Atrial Fibrillation Market Report: 2011 Edition
US$ 700.00
... is particularly significant. The report provides an analysis of the global atrial fibrillation market. It also discusses major trends, growth drivers and developments in atrial fibrillation market. The report also presents the ...
August 2011
32 pages
The para-Amino Phenol Industry in China
US$ 7,448.00
... by the demand from the downstream products especially paracetamol, para-aminophenol (PAP) industry in China keeps developing in recent years. The output of PAP ... 2010 Introduction to PAP production methods Forecast on supply and demand of in China, 2011-2015 Besides, compared with the last edition finished ...
August 2011
59 pages
External Defibrillator market in India 2011
US$ 950.00
... description of the segments in the defibrillator market in India. The market overview section provides an insight into the market and highlights the market size and growth. Import ...
August 2011
32 pages
Intravenous (IV) Solutions: Market Research Report
US$ 4,800.00
This report analyzes the worldwide markets for Intravenous (IV) Solutions in US$ Million. The report provides separate comprehensive analytics for the US, Canada ... ., Sino-Swed Pharmaceutical, Terumo Corporation, and Watson Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary ...
August 2011
274 pages
Overactive Bladder (OAB) Therapeutics: Market Research Report
US$ 4,500.00
This report analyzes the worldwide markets for Overactive Bladder (OAB) Therapeutics in US$ Million. The report provides separate comprehensive analytics for ... ., SALVAT Biotech, Sepracor Pharmaceuticals, Inc., and Watson Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary ...
August 2011
279 pages
Irritable Bowel Syndrome (IBS) Therapeutics: Market Research Report
US$ 4,500.00
This report analyzes the worldwide markets for Irritable Bowel Syndrome (IBS) Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year ...
August 2011
433 pages
Stroke Prevention in Atrial Fibrillation - View on Upcoming Milestones
US$ 90.00
DETAILED DATA FROM ARISTOTLE STUDY AT ESC – AUGUST 28th. BMY is likely to announce detailed data on Eliquis in SPAF from the ARISTOTLE study. The data on Eliquis from ARISTOTLE will be compared to the data on Pradaxa from RELY trial and not Xarelto- ROCKET AF, as there are major differences in trial design. ...
August 2011
2 pages
Eisai - Catalysts Too Weak to Mitigate Key Patent Expiries
US$ 140.00
... Nov-10 and May-13 respectively); together they contributed ~56% of revenue in FY 03/11. Eisai solely depends on catalysts coming out of its pipeline. Following Halaven approval ... , Eisai has three late stage candidates E-2007/ perampanel ...
August 2011
8 pages
Roche, BMY - Zelboraf (Vemurafenib) approval- Competition to YERVOY starts
US$ 90.00
The USFDA approval of Zelboraf (Vemurafenib) for inoperable metastatic melanoma, well in advance of the PDUFA date is encouraging. USFDA has also approved the cobas BRAF mutation diagnostic test. This will reduce YERVOY uptake directly as ~50% of Metastatic Melanoma patients are B-RAF positive and Zelboraf ...
August 2011
2 pages
Gilead - Complera Approval - Positive Long Term Impact
US$ 90.00
Approval of Complera (GILD’s Truvada + Tibotec’s Edurant) reiterates GILD’s ... HIV infection. With the current economic turmoil, approval of once-daily Complera (formerly Fixed Dose Combination drug) impact may ... report released on 12th August, 2011, titled – “Complera Approval - Positive Long Term Impact”
August 2011
5 pages
Ranbaxy - When Will The Base Business Stabilize?
US$ 140.00
We reiterate our Market Perform rating on Ranbaxy after the Q2 CY11 result that was in line with our ... about a possible timely launch. Longer term potential of Ranbaxy seems promising with Daiichi-Ranbaxy likely to become the largest generic company in Japan ...
August 2011
6 pages
Cipla - Margin Improvement - A Healthy Sign.
US$ 140.00
... higher than our earnings estimate owing to the sharp improvement in gross margin. The improvement in gross margin (up by 330 bps, Y-o-Y) is largely due to the ... day exclusivity and (2) improvement in margin as contribution from Indore facility increases. For the longer term, CIPLA’s traditional business model ...
August 2011
6 pages
Celgene - Global Share Gains Continue + Pipeline Potential
US$ 140.00
... all commercial metrics – global share and duration gains, continued expansion of market ... access through approvals and reimbursements in the US and international market, and noteworthy operating efficiency places Celgene ... – “Global Share Gains Continue + Pipeline Potential”.
August 2011
6 pages
IPCA- Margin Improvement, Despite Lower Domestic Sales
US$ 140.00
... sales in WHO member countries. We expect several growth drivers for Ipca in the near term. (1) US generics growth even without the ... WHO member countries and branded formulations (3) margin improvement as sales mix improves in favor of formulation sales. We see Ipca as the best bet in the domestic formulations ...
August 2011
5 pages
TAKEDA - Multiple Challenges Blur Future!
US$ 140.00
There are three major concerns for Takeda – 1) Takeda has got European exposure by the Nycomed acquisition, but as both ... is expected. 2) Safety related issues with Actos affects market prospects of Takeda’s key candidate Aloglipin’s combination drug with Actos and, 3) Pipeline ...
August 2011
8 pages
China Freeze Drying System Industry Report, 2011 - 2012
US$ 1,600.00
With the rapid development of pharmaceutical industry in China, the market size of freeze drying equipment continuously expands, which reached RMB2.425 billion in 2009, including the market of cleanin...
July 2011
53 pages
